Mass Spec Approaches to Supporting Biologic Development
Shimadzu Corporation: Mass Spec Approaches to Supporting Biologic Development
We welcome you to join the Shimadzu Biopharma Team to learn how the tools and methods of mass spectrometry can provide insight to the development, selection, and ultimately safe production of biologic therapeutics.
Our discussion looks at mass spec-driven workflows and will include cell culture monitoring, intact and subunit monoclonal antibody analysis, and N-glycan characterization. Whether your role in human or animal medicine is in early-stage drug development, or final product QA/QC, come see how Shimadzu’s innovative lineup of Ultra-fast LCMS detectors can provide solutions to your challenging biologics analysis through all phases of the drug life-cycle.
We will host a Q&A session after the presentation to address any questions or comments.
Presenter: Stephen Kurzyniec (Biopharma Business Development Specialist, Shimadzu Scientific Instruments)
Stephen holds degrees in biochemistry, cell biology and business administration. He has spent over 20 years in pharmaceutical R&D at both Pfizer and Lundbeck supporting various disease area programs with both small and large molecule therapies. He has extensive experience in applying a range analytical tools such as LC, LC-MS/MS, MALDI, and CE-MS. At Shimadzu, Stephen supports business development in the pharma and biopharma markets for the western US.
Presenter: Brian Domanski (Strategic Collaboration Scientist, Shimadzu Scientific Instruments)
Brian has over 10 years working to provide LC and SFC solutions for Pharma, as well as experience with a wide range of chromatography techniques including RP, NP, HILIC, IEX, SEC/GPC, and IC. His focus also includes scalable Informatics and Data Integrity solutions.